Yesterday I emailed IR for the first time in over a year, and actually got a response (previous 3 times I wrote to them I never heard back, been in the stock for 4+ years now). Funny they're engaging me, a tiny 35k share retail investor, they must truly be worried. It's clear from their reply that they have no plan for the US market, and consider it a dead end. Extremely frustrating and disappointing. Their email response just further enforced my decision to support Denner in this proxy fight.
investor.relations@amarincorp.com
Wed, Jan 18, 11:15 AM (1 day ago)
to me, investor.relations@amarincorp.com
Daniel,
Thank you for your email. Wanted to ensure to respond and provide one point of clarification to you. More than 70% of the Board and the same percent of the management team are new and have been with Amarin less than 12 months and are not the same leadership that you are referring to over the last 4 years. We agree that VASCEPA is an amazing drug. As a result of the patent loss in the US, we will not be able to realize the drug’s full potential in the US. This is why the team is focused on bringing this drug to as many market’s as possible around the globe. ROW expansion takes time and there has been significant progress. If these efforts are success, its 2023 which is the year that you will be able to see the vast majority of countries in Europe launching this drug. The current management and Board, with global market access expertise, global commercial experience, global financial experience and global medical experience are the ones with the experience and background that can make this happen.
Thank you,
Amarin IR
